ArticleBlood2012
Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007.
Article in Blood, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 313 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety and efficacy of pentoxifylline versus placebo administered as apoptosis inductor during remission induction phase of pediatric patients with acute lymphoblastic leukemia
A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL
Who cites it
313 citing papers in PubMed, 1 synthesis or guideline pooled it, 634 citations in OpenAlex.
- The efficacy and safety of nelarabine in relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis.Annals of hematology · 2025Pooled it
- Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial.Blood advances · 2022Trial
- Pharmacokinetics of tablet and liquid formulations of oral 6-mercaptopurine in children with acute lymphoblastic leukemia.Cancer chemotherapy and pharmacology · 2020Trial
- MAP3K7 is recurrently deleted in pediatric T-lymphoblastic leukemia and affects cell proliferation independently of NF-κB.BMC cancer · 2018Trial
- Clinical characteristics, prognosis, and achievement of transplant in adolescents and adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in Argentina.Hematology, transfusion and cell therapy · 2026Article
- H3K18 Lactylation Promotes Cell Proliferation in T-Cell Acute Lymphoblastic Leukemia.Journal of cellular biochemistry · 2026Article
- Bispecific Antibodies for Acute Myeloid Leukemia: From Bone Marrow Immune Niche to Clinical Translation.Antibodies (Basel, Switzerland) · 2026Review
- [Treatment strategies and prognostic factors for relapsed childhood acute lymphoblastic leukemia].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026Article
- Article
- SOHO State of the Art Updates and Next Questions | Incorporating Immunotherapy into Upfront Acute Lymphoblastic Leukemia Therapy.Clinical lymphoma, myeloma & leukemia · 2026Review
- The global epidemiology of acute myeloid leukaemia.Nature reviews. Clinical oncology · 2026Review
- A real-world data study on long-course venetoclax combined with hypomethylating agents in unfit patients.Frontiers in oncology · 2026Article
- Article
- Unraveling Research Trends and Hotspots of Genetic Variants in Acute Leukemias: A Web of Science and Scopus-Based Bibliometric Study.International journal of medical sciences · 2026Article
- Acute lymphoblastic leukemia: an update on treatment and Brazilian perspective.Frontiers in oncology · 2026Review
- Clinicopathological features of adult lymphoblastic lymphoma: a retrospective multicenter study from Türkiye.Frontiers in oncology · 2026Article
- Spatio-temporal quasi-experimental methods for rare disease outcomes: the impact of reformulated gasoline on childhood haematologic cancer.Journal of the Royal Statistical Society. Series A, (Statistics in Society) · 2025Article
- T-cell acute lymphoblastic leukemia: therapeutic outcomes in adolescents and young adults.Annals of hematology · 2025Article
- Upfront Immunotherapy Approaches in the Management of Adults with Acute Lymphoblastic Leukemia.Cancers · 2025Review
- TP53-Mutated Acute Myeloid Leukemia: Unanswered Questions.Hematological oncology · 2025Review
253 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Since 2001, the World Health Organization classification for hematopoietic and lymphoid neoplasms has provided a framework for defining acute leukemia (AL) subtypes, although few population-based studies have assessed incidence patterns and patient survival accordingly. We assessed AL incidence rates (IRs), IR ratios (IRRs), and relative survival in the United States (2001-2007) in one of the first population-based, comprehensive assessments. Most subtypes of acute myeloid leukemia (AML) and acute lymphoblastic leukemia/lymphoma (ALL/L) predominated among males, from twice higher incidence of T-cell ALL/L among males than among females (IRR = 2.20) to nearly equal IRs of acute promyelocytic leukemia (APL; IRR = 1.08). Compared with non-Hispanic whites, Hispanics had significantly higher incidence of B-cell ALL/L (IRR = 1.64) and APL (IRR = 1.28); blacks had lower IRs of nearly all AL subtypes. All ALL/L but only some AML subtypes were associated with a bimodal age pattern. Among AML subtypes, survival was highest for APL and AML with inv(16). B-cell ALL/L had more favorable survival than T-cell ALL/L among the young; the converse occurred at older ages. Limitations of cancer registry data must be acknowledged, but the distinct AL incidence and survival patterns based on the World Health Organization classification support biologic diversity that should facilitate etiologic discovery, prognostication, and treatment advances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.